Skip to content

    Psilocybin-Assisted Therapy in Lung Cancer: Clinical Trial Design and Early Results

    Can psilocybin-assisted therapy relieve major depression and existential distress when traditional psychiatric treatments fall short for patients with advanced lung cancer? Patients diagnosed with advanced lung cancer frequently experience severe emotional complications, including major depressive disorder, anxiety, and profound existential distress, yet conventional antidepressants and standard psychotherapy often fail to meet their needs. In this 10-minute interview with Oncology Data Advisor, Alan Davis, PhD, Associate Professor and Director of the Center for Psychedelic Drug Research and Education at The Ohio State University, discusses the first clinical trial evaluating psilocybin-assisted therapy specifically in patients with lung cancer, outlining the structured three-phase therapeutic model, early safety and efficacy signals, and potential links to treatment adherence and systemic inflammation. Read the full accompanying article on Oncology Data Advisor: https://bit.ly/4AIDXTp What You Will Learn in This Episode 🔹 Unmet Psychiatric Needs in Advanced Lung Cancer: Why advanced-stage lung cancer diagnoses create an acute existential burden and ongoing trauma that often resist traditional antidepressants and conventional psychotherapy. 🔹 The Three-Phase Treatment Protocol: How the manualized clinical framework pairs roughly eight hours of preparation with two dedicated therapists, a full-day supervised high-dose psilocybin session with music, and multi-week psychological integration. 🔹 Interdependence of Psychotherapy and Pharmacology: Why building trust and psychological safety prior to dosing directly influences therapeutic response, functioning as a unified clinical package rather than a standalone medication.